Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LGVN

Longeveron Inc

Dec 08 • 04:00PM ET

2.27

Dollar change -0.10
Percentage change -4.22	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.98	Insider Own	69.06%	Shs Outstand	23.75M	Perf Week	15.23%
Market Cap	53.91M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	-0.14%	Shs Float	7.35M	Perf Month	15.23%
Income	-20.64M	PEG	-	EPS next Q	-0.21	Inst Own	2.40%	Short Float / Ratio	6.66% / 1.77	Perf Quarter	-6.58%
Sales	0.77M	P/S	70.02	EPS this Y	-6.30%	Inst Trans	3.97%	Short Interest	0.49M	Perf Half Y	-33.63%
Book/sh	0.32	P/B	7.19	EPS next Y	17.77%	ROA	-93.72%	Target Price	9.43	Perf Year	-34.20%
Cash/sh	0.17	P/C	13.72	EPS next 5Y	-	ROE	-126.19%	52W Range	1.50 - 4.58	Perf YTD	-29.50%
Dividend	-	P/FCF	-	EPS past 5Y	-28.28%	ROI	-247.74%	52W High	-50.43%	Beta	0.62
Dividend %	-	Quick Ratio	1.49	Sales past 5Y	20.19%	Gross Margin	-101.17%	52W Low	51.33%	ATR	0.18
Employees	19	Current Ratio	1.49	Sales Q/Q	-43.40%	Oper. Margin	-2715.51%	RSI (14)	64.40	Volatility	9.26% 8.86%
Optionable	No	Debt/Eq	0.33	EPS Q/Q	-11.65%	Profit Margin	-2690.87%	Rel Volume	0.17	Prev Close	2.37
Shortable	Yes	LT Debt/Eq	0.24	Earnings	Nov 10 BMO	Payout	-	Avg Volume	276.07K	Price	2.27
Recom	1.00	SMA20	16.32%	SMA50	15.47%	SMA200	-18.01%	Volume	46,145	Change	-4.22%

Nov-14-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc. (GlobeNewswire)
Nov-11-23 09:00AM	Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
08:38AM	Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:30AM	Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire) -5.70%
Nov-03-23 08:00AM	Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 (GlobeNewswire)
08:30AM	Loading…
Oct-24-23 08:30AM	Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B for the Treatment of Mild Alzheimer's (GlobeNewswire)
Oct-13-23 04:05PM	Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-12-23 08:00AM	Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.24%
Oct-05-23 07:00AM	Longeveron Announces Positive Top-Line Results for Lomecel-B in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.73%
Sep-12-23 09:00AM	Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market (News Direct)
Sep-11-23 08:00AM	Longeveron Issues Letter to Stockholders (GlobeNewswire)
Sep-07-23 08:30AM	IBN Coverage Initiated for Longeveron Inc. (GlobeNewswire)
08:00AM	Long-term Survival Data from Longeverons ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
Sep-05-23 08:00AM	Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
08:00AM	Loading…
Aug-29-23 08:00AM	Longeveron to Participate in the 149th Annual National Investment Banking Association Conference (GlobeNewswire)
Aug-22-23 08:00AM	Longeveron Rights Offering Subscription Period Begins (GlobeNewswire) +8.20%
Aug-16-23 09:13AM	Longeveron Rights Offering Declared Effective and Calendar Finalized (GlobeNewswire)
Aug-14-23 04:05PM	Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B on August 16, 2023 (GlobeNewswire) -7.03%
08:00AM	Longeveron Announces Pricing for Rights Offering and Expected Calendar (GlobeNewswire)
Aug-11-23 07:30AM	Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
07:24AM	LGVN Makes Progress in Treatment for Devastating Diseases (Zacks Small Cap Research)
07:00AM	Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B in Hypoplastic Left Heart Syndrome (GlobeNewswire)
Aug-08-23 09:25AM	Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions (News Direct)
07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:00AM	Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Longeveron Appoints Lisa Locklear as Chief Financial Officer (GlobeNewswire)
Jul-11-23 08:00AM	Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer (GlobeNewswire)
Jul-10-23 08:00AM	Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors (GlobeNewswire)
Jul-07-23 09:00AM	HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate Could Longeverons Lomecel-B Improve Outcomes? (News Direct)
11:12AM	Loading…
Jul-06-23 11:12AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.) -5.66%
Jun-27-23 06:07PM	Longeveron Files Registration Statement for Rights Offering (GlobeNewswire) -5.85%
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire)
May-12-23 08:32AM	LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates (InvestorPlace)
08:20AM	LGVN: Announces Results and Progress on a Devastating Disease (Zacks Small Cap Research)
08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 05:23PM	Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free (Benzinga) +26.58%
08:30AM	Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (GlobeNewswire)
May-08-23 08:30AM	Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023 (GlobeNewswire)
Apr-19-23 08:59AM	Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B for Aging-Related Frailty in Japan (GlobeNewswire)
Mar-14-23 02:38PM	Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51% (Simply Wall St.)
Mar-10-23 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -11.49%
06:10AM	LGVN: Longeveron Continues Progress Toward Important Treatments (Zacks Small Cap Research)
Mar-07-23 04:18PM	Insiders Just Bought $1 Million of This Deep Value Tech Stock (InvestorPlace)
Mar-06-23 08:30AM	Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023 (GlobeNewswire)
Feb-28-23 08:30AM	Longeveron Appoints Wael Hashad as Chief Executive Officer (GlobeNewswire)
Jan-27-23 08:51AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.)
Jan-19-23 08:35AM	LGVN: Longeveron Posts Positive Results for Life-Threatening Condition (Zacks Small Cap Research)
08:30AM	Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal (GlobeNewswire)
Jan-06-23 09:58AM	UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire) +9.51%
08:30AM	Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Nov-29-22 04:30PM	Longeveron to Participate in Upcoming 2022 Investor Conferences (GlobeNewswire) -9.18%
Nov-16-22 05:32AM	Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-14-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
07:15AM	LGVN: Making Exciting Progress (Zacks Small Cap Research)
Nov-10-22 08:30AM	Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B for the Treatment of Alzheimers Disease (GlobeNewswire) +15.85%
Nov-07-22 09:06AM	Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-05-22 02:34PM	Investing in Longeveron (NASDAQ:LGVN) a year ago would have delivered you a 13% gain (Simply Wall St.)
11:00AM	Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market (InvestorPlace)
08:30AM	Longeveron to Present at the Annual Dawson James Small Cap Growth Conference (GlobeNewswire)
Sep-15-22 08:30AM	Longeveron Names Jerome Bailey Vice President of Business Operations (GlobeNewswire)
Sep-06-22 08:30AM	Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 08:30AM	U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeverons Lomecel-B Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants (GlobeNewswire) -7.80%
07:30AM	EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants (Benzinga)
Aug-25-22 08:00AM	Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B Cell Therapy Through Levels of Vascular Biomarker (GlobeNewswire)
07:30AM	EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent (Benzinga)
Aug-20-22 08:45AM	We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate (Simply Wall St.)
Aug-12-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
07:36AM	LGVN: Quarterly Report Provides Good News (Zacks Small Cap Research)
Aug-08-22 08:30AM	Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022 (GlobeNewswire)
Jul-27-22 09:33AM	LGVN: Alzheimers Study Gains Traction as CEO Search Continues (Zacks Small Cap Research)
Jul-07-22 08:00AM	Longeveron Announces Abstract Accepted for Presentation at the Alzheimers Association International Conference (AAIC) (GlobeNewswire) +21.18%
Jun-26-22 10:22AM	What Type Of Shareholders Make Up Longeveron Inc.'s (NASDAQ:LGVN) Share Registry? (Simply Wall St.)
May-21-22 10:16AM	Multiple insiders bought Longeveron Inc. (NASDAQ:LGVN) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-13-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.80%
07:12AM	LGVN: CEO Leaving but Progress Continues (Zacks Small Cap Research)
May-09-22 04:15PM	Longeveron Announces CEO Transition (GlobeNewswire)
08:30AM	Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022 (GlobeNewswire)
Apr-28-22 01:53PM	Investors in Longeveron (NASDAQ:LGVN) have made a favorable return of 78% over the past year (Simply Wall St.) -6.00%
Apr-14-22 08:58AM	Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimers Symposium; International Frailty and Sarcopenia Research Conference (GlobeNewswire) +5.03%
Apr-13-22 08:00AM	Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimers Trial (GlobeNewswire) -6.41%
07:30AM	EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial (Benzinga)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace) -9.21%
Apr-05-22 08:00AM	Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -9.73%
Apr-01-22 06:30AM	LGVN: LGVN Publishes Positive Alzheimers Results (Zacks Small Cap Research) +13.12%
Mar-31-22 08:00AM	Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimers Disease in Alzheimers & Dementia®: The Journal of the Alzheimers Association (GlobeNewswire) +105.36%
07:48AM	Midday Stock Movers: Longeveron Surges, Dell, UiPath, Expensify Plunge (Investing.com)
07:30AM	EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal (Benzinga)
Mar-24-22 08:00AM	Longeveron Presents at Second Euro-Geroscience Conference (GlobeNewswire) +9.20%
Mar-15-22 04:54PM	My No. 2 Stock Pick For 2022 Rises 100% (InvestorPlace)
08:00AM	Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-11-22 08:00AM	Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress (GlobeNewswire)
06:10AM	LGVN: Longeveron Continues to Make Progress (Zacks Small Cap Research)
Mar-07-22 08:00AM	Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022 (GlobeNewswire) -8.93%
Mar-02-22 08:00AM	Longeveron to Present at Q1 Virtual Investor Summit Conference (GlobeNewswire)
Feb-17-22 08:00AM	Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors (GlobeNewswire) -7.25%
Jan-27-22 05:38PM	TAP Consulting, LLC Buys Vanguard Information Technology ETF, Vanguard Health Care ETF, PayPal ... (GuruFocus.com) -11.76%
04:49PM	3 Stocks Insiders Are Buying on Market Turbulence (InvestorPlace)
Jan-26-22 09:10AM	LGVN: Using Cellular Technology to Ease Major Medical Issues (Zacks Small Cap Research) +13.01%
Jan-25-22 08:00AM	Longeveron to Participate in Phacilitate Advanced Therapies Week (GlobeNewswire) +5.52%

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hare Joshua	Chief Scientific Officer	Sep 21	Option Exercise	3.00	5,000	15,000	7,828,263	Sep 22 07:00 PM
Lehr Paul T	General Counsel, Secretary	Sep 20	Option Exercise	3.00	2,000	6,000	144,213	Sep 21 05:00 PM
Hare Joshua	Chief Scientific Officer	Sep 12	Option Exercise	3.00	30,000	90,000	7,823,263	Sep 14 05:09 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Sep 12	Option Exercise	3.00	10,000	30,000	47,566	Sep 13 05:00 PM
Soffer Rock	Director	Sep 08	Option Exercise	3.00	30,000	90,000	702,351	Sep 12 05:00 PM
Clavijo James	CFO and Treasurer	Jun 29	Sale	3.51	5,000	17,550	47,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 28	Sale	3.43	10,000	34,300	52,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 27	Sale	3.48	8,532	29,691	62,303	Jun 29 05:00 PM
Hare Joshua	Chief Scientific Officer	Jan 27	Sale	4.28	20,000	85,600	7,793,263	Jan 30 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGVN

Longeveron Inc

Upgrade your FINVIZ experience